The Pharmacist’s Role in Ending the HIV Epidemic Information You Need to Keep Your Practice Up to Date

James D. Scott, PharmD, FCCP, APh, AAHIVP; Lucas Hill, PharmD, BCACP, AAHIVP


Jointly provided by the Postgraduate Institute for Medicine and Integritas Communications


This activity is supported by an independent educational grant from Gilead Sciences, Inc.


Primary Presenter
James D. Scott, PharmD, FCCP, APh, AAHIVP
Associate Dean for Experiential and Professional Affairs
Western University of Health Sciences College of Pharmacy
Pomona, California

Faculty Commentator
Lucas Hill, PharmD, BCACP, AAHIVP
HIV/HCV Pharmacist Specialist
UC San Diego Health System
San Diego, California

Pro​gram Description

This enduring activity presents the fundamentals of human immunodeficiency virus (HIV) prevention through the implementation of preexposure prophylaxis (PrEP) services. Emphasis will be placed on taking a sexual history, screening, and risk-assessment, as well as current treatment regimens and protocols for appropriate initiation and monitoring of PrEP. It will also discuss the potential new role for expanded care by pharmacy providers, and the specific changes and opportunities for those in California in an environment of expanded pharmacy scope of practice. The program will equip pharmacists with the most recent clinical and pharmacologic information based on the guidelines of the American Society of Health Systems Pharmacists (ASHP) and the US Public Health Service clinical practice guidelines. The activity will show the important roles that pharmacists play as trusted members of the HIV-prevention team, as links to care, and as potential PrEP providers.

Target Audience

This activity is intended for clinical and community pharmacists involved in the care of patients at risk for HIV infection.

Educational Objectives

Upon completion of this activity, participants will be better able to:

  • Demonstrate understanding of the epidemiology, burden, and stigma surrounding HIV risk and transmission
  • Utilize practice guidelines to screen for HIV risk and determine clinical eligibility for PrEP
  • Compare prescribing options for PrEP in terms of efficacy, safety, and dosing regimens

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Integritas Communications. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Continuing Pharmacy Education

Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. (Universal Activity Number – JA4008162-9999-20-2211-H01-P).

This is a knowledge-based activity.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Lucas Hill, PharmD, BCACP, AAHIVP: Nothing to disclose

James D. Scott, PharmD, FCCP, APh, AAHIVP: Nothing to disclose

Planners and Managers

The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Instructions To Receive Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, complete and receive a minimum score of 80% on the posttest, and complete the program evaluation.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

CPE Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via email at or at

Integritas Contact Information

For all other questions regarding this monograph, please contact Integritas via email at


We would like to thank the American Academy of HIV Medicine (AAHIVM) for their collaboration and support.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

expiration 10/16/2021

type POC101